Skip to main content
Erschienen in: Archives of Dermatological Research 5/2011

01.07.2011 | Original Paper

Neurofibromatosis type 1 (NF1) and pheochromocytoma: prevalence, clinical and cardiovascular aspects

verfasst von: Laura Zinnamosca, Luigi Petramala, Dario Cotesta, Cristiano Marinelli, Mauro Schina, Rosario Cianci, Sandra Giustini, Susanna Sciomer, Emanuela Anastasi, Stefano Calvieri, Giorgio De Toma, Claudio Letizia

Erschienen in: Archives of Dermatological Research | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

The aim of the study was to evaluate the prevalence of pheochromocytoma (PHEO) in patients with neurofibromatosis type 1 (NF1), and to analyze the behavior of some anthropometric and cardiovascular parameters. In 48 consecutive NF1 patients, urinary metanephrines and vanillylmandelic acid excretion were assessed. The body mass index (BMI), waist circumference (WC), ambulatory blood pressure monitoring (ABPM), echocardiography and ultrasound carotid arterial wall evaluation were performed. In NF1 patients, 11 (29.3%) had arterial hypertension, 7 (14.6%) had a PHEO. Four (57%) NF1 patients with PHEO were symptomatic at the diagnosis. In PHEO-NF1 patients, we revealed a lower BMI and WC values with respect to NF1 patients without PHEO and normal subjects (NSs) (p < 0.05), respectively. The nocturnal non-dipping pattern at the ABPM was present in 40.4% of NF1 patients, and in particular this phenomenon was present in PHEO-NF1 patients (71.4%). Left ventricular mass index and intima media thickness were significantly higher in NF1 patients as compared to NS (p < 0.05), particularly in NF1-PHEO patients (p < 0.05). In conclusions, these findings revealed high prevalence of PHEO in NF1 patients and suggest that, in addition to blood pressure, humoral factors (increased sympathetic activity or neurofibromin), influence the pathogenesis of remodeling of cardiovascular system.
Literatur
1.
Zurück zum Zitat Bausch B, Borozdin W, Mautner VF et al (2007) Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab 92(7):2784–2792PubMedCrossRef Bausch B, Borozdin W, Mautner VF et al (2007) Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab 92(7):2784–2792PubMedCrossRef
2.
Zurück zum Zitat Bravo EL, Tagle R (2003) Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 24:539–553PubMedCrossRef Bravo EL, Tagle R (2003) Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 24:539–553PubMedCrossRef
3.
Zurück zum Zitat Ceruti M, Petramala L, Cotesta D et al (2006) Ambulatory blood pressure monitoring in secondary arterial hypertension due to adrenal diseases. J Clin Hypertens 8:642–648CrossRef Ceruti M, Petramala L, Cotesta D et al (2006) Ambulatory blood pressure monitoring in secondary arterial hypertension due to adrenal diseases. J Clin Hypertens 8:642–648CrossRef
4.
Zurück zum Zitat Cichowski K, Jacks T (2001) NF1 tumor suppressor gene function: narrowing the GAP. Cell 104:593–604PubMedCrossRef Cichowski K, Jacks T (2001) NF1 tumor suppressor gene function: narrowing the GAP. Cell 104:593–604PubMedCrossRef
5.
Zurück zum Zitat Cotesta D, Erlic Z, Petramala L et al (2008) Coincidence of neurofibromatosis Type 1 and multiple endocrine neoplasia type 2. Endocrinologist 18:277–281CrossRef Cotesta D, Erlic Z, Petramala L et al (2008) Coincidence of neurofibromatosis Type 1 and multiple endocrine neoplasia type 2. Endocrinologist 18:277–281CrossRef
6.
Zurück zum Zitat Denolle T, Chatellier G, Julien J et al (1993) Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma. Am J Hypertens 6:907–913PubMed Denolle T, Chatellier G, Julien J et al (1993) Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma. Am J Hypertens 6:907–913PubMed
7.
Zurück zum Zitat Ferner RE, Huson SM, Thomas N et al (2007) Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 44(2):81–88PubMedCrossRef Ferner RE, Huson SM, Thomas N et al (2007) Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 44(2):81–88PubMedCrossRef
8.
10.
Zurück zum Zitat Goldberg NS, Roenigk RK (1996) Neurofibromatosis, tuberous sclerosis, and other neurocutaneous discorde. In: Wintronb BU (ed) Cutaneous medicine and surgery: an interpretated program in dermatology. WB Saunders, Philadelpfia, pp 1729–1741 Goldberg NS, Roenigk RK (1996) Neurofibromatosis, tuberous sclerosis, and other neurocutaneous discorde. In: Wintronb BU (ed) Cutaneous medicine and surgery: an interpretated program in dermatology. WB Saunders, Philadelpfia, pp 1729–1741
11.
Zurück zum Zitat Goldstein DS, Eisenhofer G, Flynn JA et al (2004) Diagnosis and localization of pheochromocytoma. Hypertension 43:907–910PubMedCrossRef Goldstein DS, Eisenhofer G, Flynn JA et al (2004) Diagnosis and localization of pheochromocytoma. Hypertension 43:907–910PubMedCrossRef
12.
Zurück zum Zitat Gutmann DH, Aylsworth A, Carey JC et al (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278:51–57PubMedCrossRef Gutmann DH, Aylsworth A, Carey JC et al (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278:51–57PubMedCrossRef
13.
Zurück zum Zitat Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C (2006) Ambulatory blood pressure monitoring and risk of cardiovascular disease: a population based study. Am J Hypertens 19(3):243–250PubMedCrossRef Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C (2006) Ambulatory blood pressure monitoring and risk of cardiovascular disease: a population based study. Am J Hypertens 19(3):243–250PubMedCrossRef
14.
Zurück zum Zitat Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7:589–600PubMedCrossRef Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7:589–600PubMedCrossRef
15.
Zurück zum Zitat Heniford BT, Arca MJ, Walsh RM, Gill IS (1999) Laparoscopic adrenalectomy for cancer. Semin Surg Oncol 16(4):293–306PubMedCrossRef Heniford BT, Arca MJ, Walsh RM, Gill IS (1999) Laparoscopic adrenalectomy for cancer. Semin Surg Oncol 16(4):293–306PubMedCrossRef
16.
Zurück zum Zitat Huson SM, Compston DA, Clark P et al (1989) A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 26:704–711PubMedCrossRef Huson SM, Compston DA, Clark P et al (1989) A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 26:704–711PubMedCrossRef
17.
Zurück zum Zitat Ito Y, Fujimoto Y, Obara T (1992) The role of epinephrine, norepinephrine, and dopamine in blood pressure disturbances in patients with pheochromocytoma. World J Surg 16:759–763PubMedCrossRef Ito Y, Fujimoto Y, Obara T (1992) The role of epinephrine, norepinephrine, and dopamine in blood pressure disturbances in patients with pheochromocytoma. World J Surg 16:759–763PubMedCrossRef
18.
Zurück zum Zitat Jenne DE, Tinschert S, Reimann H et al (2001) Molecular characterization and gene content of breakpoint boundaries in patients with neurofibromatosis type 1 with 17q11.2 microdeletions. Am J Hum Genet 69:516–527PubMedCrossRef Jenne DE, Tinschert S, Reimann H et al (2001) Molecular characterization and gene content of breakpoint boundaries in patients with neurofibromatosis type 1 with 17q11.2 microdeletions. Am J Hum Genet 69:516–527PubMedCrossRef
19.
Zurück zum Zitat Kurpad AV, Khan K, Calder AG, Elia M (1994) Muscle and whole body metabolism after norepinephrine. Am J Physiol 266:E877–E884PubMed Kurpad AV, Khan K, Calder AG, Elia M (1994) Muscle and whole body metabolism after norepinephrine. Am J Physiol 266:E877–E884PubMed
20.
Zurück zum Zitat La Batide-Alanore A, Chatellier G, Plouin PF (2003) Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertension 21:1703–1707CrossRef La Batide-Alanore A, Chatellier G, Plouin PF (2003) Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertension 21:1703–1707CrossRef
21.
Zurück zum Zitat Lakkis MM, Epstein JA (1998) Neurofibromin modulation of Ras activity is required for normal endocardial-mesenchymal transformation in the developing heart. Development 125:4359–4367PubMed Lakkis MM, Epstein JA (1998) Neurofibromin modulation of Ras activity is required for normal endocardial-mesenchymal transformation in the developing heart. Development 125:4359–4367PubMed
22.
23.
Zurück zum Zitat Mancia G, Ferrari A, Gregorini L et al (1983) Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 53:96–104PubMed Mancia G, Ferrari A, Gregorini L et al (1983) Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 53:96–104PubMed
24.
Zurück zum Zitat Mannelli M, Ianni L, Cilotti A et al (1999) Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 141:619–624PubMedCrossRef Mannelli M, Ianni L, Cilotti A et al (1999) Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 141:619–624PubMedCrossRef
25.
Zurück zum Zitat Millar-Craig MW, Bishop CN, Raftery EB (1978) Circadian variation of blood-pressure. Lancet 1:795–797PubMedCrossRef Millar-Craig MW, Bishop CN, Raftery EB (1978) Circadian variation of blood-pressure. Lancet 1:795–797PubMedCrossRef
26.
Zurück zum Zitat Norton KK, Xu J, Gutmann DH (1995) Expression of the neurofibromatosis I gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. Neurobiol Dis 2:13–21PubMedCrossRef Norton KK, Xu J, Gutmann DH (1995) Expression of the neurofibromatosis I gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. Neurobiol Dis 2:13–21PubMedCrossRef
27.
28.
Zurück zum Zitat Pacak K, Linehan WM, Eisenhofer G et al (2001) Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134:315–329PubMed Pacak K, Linehan WM, Eisenhofer G et al (2001) Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134:315–329PubMed
29.
Zurück zum Zitat Palatini P, Penzo M, Racioppa A et al (1992) Clinical relevance of nighttime blood pressure and of daytime blood pressure variability. Arch Intern Med 152:1855–1860PubMedCrossRef Palatini P, Penzo M, Racioppa A et al (1992) Clinical relevance of nighttime blood pressure and of daytime blood pressure variability. Arch Intern Med 152:1855–1860PubMedCrossRef
30.
Zurück zum Zitat Rizzoni D, Muiesan ML, Porteri E et al (1998) Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol 32:985–992PubMedCrossRef Rizzoni D, Muiesan ML, Porteri E et al (1998) Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol 32:985–992PubMedCrossRef
31.
Zurück zum Zitat Routledge F, McFetridge-Durdle J (2007) Non-dipping blood pressure patterns among individuals with essential hypertension: a review of the literature. Eur J Cardiovasc Nurs 6:9–26PubMedCrossRef Routledge F, McFetridge-Durdle J (2007) Non-dipping blood pressure patterns among individuals with essential hypertension: a review of the literature. Eur J Cardiovasc Nurs 6:9–26PubMedCrossRef
32.
Zurück zum Zitat Shub C, Cueto-Garcia L, Sheps SG et al (1986) Echocardiographic findings in pheochromocytoma. Am J Cardiol 57:971–975PubMedCrossRef Shub C, Cueto-Garcia L, Sheps SG et al (1986) Echocardiographic findings in pheochromocytoma. Am J Cardiol 57:971–975PubMedCrossRef
33.
Zurück zum Zitat Tedesco MA, Di Salvo G, Natale F, Pergola V, Calabrese E, Grassia C, Ratti G, Iarussi D, Iacono A, Calabrò R, Lama G (2002) The heart in neurofibromatosis type 1: an echocardiographic study. Heart J. 143:883–888CrossRef Tedesco MA, Di Salvo G, Natale F, Pergola V, Calabrese E, Grassia C, Ratti G, Iarussi D, Iacono A, Calabrò R, Lama G (2002) The heart in neurofibromatosis type 1: an echocardiographic study. Heart J. 143:883–888CrossRef
34.
Zurück zum Zitat Walther MM, Herring J, Enquist E et al (1999) von Recklinghausen’s disease and pheochromocytomas. J Urol 162:1582–1586PubMedCrossRef Walther MM, Herring J, Enquist E et al (1999) von Recklinghausen’s disease and pheochromocytomas. J Urol 162:1582–1586PubMedCrossRef
35.
Zurück zum Zitat Xu J, Ismat FA, Wang T et al (2009) Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction. Circ Res 105:304–311PubMedCrossRef Xu J, Ismat FA, Wang T et al (2009) Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction. Circ Res 105:304–311PubMedCrossRef
Metadaten
Titel
Neurofibromatosis type 1 (NF1) and pheochromocytoma: prevalence, clinical and cardiovascular aspects
verfasst von
Laura Zinnamosca
Luigi Petramala
Dario Cotesta
Cristiano Marinelli
Mauro Schina
Rosario Cianci
Sandra Giustini
Susanna Sciomer
Emanuela Anastasi
Stefano Calvieri
Giorgio De Toma
Claudio Letizia
Publikationsdatum
01.07.2011
Verlag
Springer-Verlag
Erschienen in
Archives of Dermatological Research / Ausgabe 5/2011
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-010-1090-z

Weitere Artikel der Ausgabe 5/2011

Archives of Dermatological Research 5/2011 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.